Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.
Identifieur interne : 000030 ( PubMed/Corpus ); précédent : 000029; suivant : 000031Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.
Auteurs : Mizuho Suzuki ; Masatoshi Okamatsu ; Takahiro Hiono ; Keita Matsuno ; Yoshihiro SakodaSource :
- The Journal of veterinary medical science [ 1347-7439 ] ; 2017.
English descriptors
- KwdEn :
- Animals, Cross Reactions (immunology), Female, Influenza A virus (genetics), Influenza A virus (immunology), Influenza Vaccines (immunology), Influenza Vaccines (pharmacology), Mice, Mice, Inbred BALB C, Neutralization Tests (veterinary), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Phylogeny, Sequence Analysis, DNA, Vaccines, Inactivated (immunology), Vaccines, Inactivated (pharmacology).
- MESH :
- chemical , immunology : Influenza Vaccines, Vaccines, Inactivated.
- genetics : Influenza A virus.
- immunology : Cross Reactions, Influenza A virus, Orthomyxoviridae Infections.
- chemical , pharmacology : Influenza Vaccines, Vaccines, Inactivated.
- prevention & control : Orthomyxoviridae Infections.
- veterinary : Neutralization Tests.
- virology : Orthomyxoviridae Infections.
- Animals, Female, Mice, Mice, Inbred BALB C, Phylogeny, Sequence Analysis, DNA.
Abstract
H2N2 influenza virus caused a pandemic starting in 1957 but has not been detected in humans since 1968. Thus, most people are immunologically naive to viruses of the H2 subtype. In contrast, H2 influenza viruses are continually isolated from wild birds, and H2N3 viruses were isolated from pigs in 2006. H2 influenza viruses could cause a pandemic if re-introduced into humans. In the present study, a vaccine against H2 influenza was prepared as an effective control measure against a future human pandemic. A/duck/Hokkaido/162/2013 (H2N1), which showed broad antigenic cross-reactivity, was selected from the candidate H2 influenza viruses recently isolated from wild birds in Asian countries. Sufficient neutralizing antibodies against homologous and heterologous viruses were induced in mice after two subcutaneous injections of the inactivated whole virus particle vaccine. The inactivated vaccine induced protective immunity sufficient to reduce the impact of challenges with A/swine/Missouri/2124514/2006 (H2N3). This study demonstrates that the inactivated whole virus particle vaccine prepared from an influenza virus library would be useful against a future H2 influenza pandemic.
DOI: 10.1292/jvms.17-0312
PubMed: 28993601
Links to Exploration step
pubmed:28993601Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.</title><author><name sortKey="Suzuki, Mizuho" sort="Suzuki, Mizuho" uniqKey="Suzuki M" first="Mizuho" last="Suzuki">Mizuho Suzuki</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Okamatsu, Masatoshi" sort="Okamatsu, Masatoshi" uniqKey="Okamatsu M" first="Masatoshi" last="Okamatsu">Masatoshi Okamatsu</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Hiono, Takahiro" sort="Hiono, Takahiro" uniqKey="Hiono T" first="Takahiro" last="Hiono">Takahiro Hiono</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Matsuno, Keita" sort="Matsuno, Keita" uniqKey="Matsuno K" first="Keita" last="Matsuno">Keita Matsuno</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Sakoda, Yoshihiro" sort="Sakoda, Yoshihiro" uniqKey="Sakoda Y" first="Yoshihiro" last="Sakoda">Yoshihiro Sakoda</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28993601</idno><idno type="pmid">28993601</idno><idno type="doi">10.1292/jvms.17-0312</idno><idno type="wicri:Area/PubMed/Corpus">000030</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000030</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.</title><author><name sortKey="Suzuki, Mizuho" sort="Suzuki, Mizuho" uniqKey="Suzuki M" first="Mizuho" last="Suzuki">Mizuho Suzuki</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Okamatsu, Masatoshi" sort="Okamatsu, Masatoshi" uniqKey="Okamatsu M" first="Masatoshi" last="Okamatsu">Masatoshi Okamatsu</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Hiono, Takahiro" sort="Hiono, Takahiro" uniqKey="Hiono T" first="Takahiro" last="Hiono">Takahiro Hiono</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Matsuno, Keita" sort="Matsuno, Keita" uniqKey="Matsuno K" first="Keita" last="Matsuno">Keita Matsuno</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Sakoda, Yoshihiro" sort="Sakoda, Yoshihiro" uniqKey="Sakoda Y" first="Yoshihiro" last="Sakoda">Yoshihiro Sakoda</name><affiliation><nlm:affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Journal of veterinary medical science</title><idno type="eISSN">1347-7439</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cross Reactions (immunology)</term><term>Female</term><term>Influenza A virus (genetics)</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (pharmacology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests (veterinary)</term><term>Orthomyxoviridae Infections (immunology)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Orthomyxoviridae Infections (virology)</term><term>Phylogeny</term><term>Sequence Analysis, DNA</term><term>Vaccines, Inactivated (immunology)</term><term>Vaccines, Inactivated (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cross Reactions</term><term>Influenza A virus</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="veterinary" xml:lang="en"><term>Neutralization Tests</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Phylogeny</term><term>Sequence Analysis, DNA</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">H2N2 influenza virus caused a pandemic starting in 1957 but has not been detected in humans since 1968. Thus, most people are immunologically naive to viruses of the H2 subtype. In contrast, H2 influenza viruses are continually isolated from wild birds, and H2N3 viruses were isolated from pigs in 2006. H2 influenza viruses could cause a pandemic if re-introduced into humans. In the present study, a vaccine against H2 influenza was prepared as an effective control measure against a future human pandemic. A/duck/Hokkaido/162/2013 (H2N1), which showed broad antigenic cross-reactivity, was selected from the candidate H2 influenza viruses recently isolated from wild birds in Asian countries. Sufficient neutralizing antibodies against homologous and heterologous viruses were induced in mice after two subcutaneous injections of the inactivated whole virus particle vaccine. The inactivated vaccine induced protective immunity sufficient to reduce the impact of challenges with A/swine/Missouri/2124514/2006 (H2N3). This study demonstrates that the inactivated whole virus particle vaccine prepared from an influenza virus library would be useful against a future H2 influenza pandemic.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28993601</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1347-7439</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of veterinary medical science</Title><ISOAbbreviation>J. Vet. Med. Sci.</ISOAbbreviation></Journal><ArticleTitle>Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.</ArticleTitle><Pagination><MedlinePgn>1815-1821</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1292/jvms.17-0312</ELocationID><Abstract><AbstractText>H2N2 influenza virus caused a pandemic starting in 1957 but has not been detected in humans since 1968. Thus, most people are immunologically naive to viruses of the H2 subtype. In contrast, H2 influenza viruses are continually isolated from wild birds, and H2N3 viruses were isolated from pigs in 2006. H2 influenza viruses could cause a pandemic if re-introduced into humans. In the present study, a vaccine against H2 influenza was prepared as an effective control measure against a future human pandemic. A/duck/Hokkaido/162/2013 (H2N1), which showed broad antigenic cross-reactivity, was selected from the candidate H2 influenza viruses recently isolated from wild birds in Asian countries. Sufficient neutralizing antibodies against homologous and heterologous viruses were induced in mice after two subcutaneous injections of the inactivated whole virus particle vaccine. The inactivated vaccine induced protective immunity sufficient to reduce the impact of challenges with A/swine/Missouri/2124514/2006 (H2N3). This study demonstrates that the inactivated whole virus particle vaccine prepared from an influenza virus library would be useful against a future H2 influenza pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Mizuho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamatsu</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiono</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuno</LastName><ForeName>Keita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Kita 18 Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakoda</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Microbiology, Faculty of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Kita 18 Nishi 9, Kita-ku, Sapporo 060-0818, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Vet Med Sci</MedlineTA><NlmUniqueID>9105360</NlmUniqueID><ISSNLinking>0916-7250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017422" MajorTopicYN="N">Sequence Analysis, DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">H2 influenza</Keyword><Keyword MajorTopicYN="N">antigenicity</Keyword><Keyword MajorTopicYN="N">pre-pandemic</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28993601</ArticleId><ArticleId IdType="doi">10.1292/jvms.17-0312</ArticleId><ArticleId IdType="pmc">PMC5709558</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Virol. 2000;145(6):1059-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10948982</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1982 Oct 15;122(1):38-47</Citation><ArticleIdList><ArticleId IdType="pubmed">6182687</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(12):e50834</Citation><ArticleIdList><ArticleId IdType="pubmed">23226543</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Mar 10;471(7337):157-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21390107</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Jan;3(1):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19453438</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2014 Oct;159(10):2567-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24824346</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vet Med Sci. 2012 Apr;74(4):441-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22123308</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1995;140(7):1163-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7646350</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Jan 8;28(3):780-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19857455</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(5):e37220</Citation><ArticleIdList><ArticleId IdType="pubmed">22623997</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Mar 1;398(1):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 1997 Oct;41(5):251-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9607078</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2015 Aug;51(1):57-68</Citation><ArticleIdList><ArticleId IdType="pubmed">26036326</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2011 Feb 11;8:65</Citation><ArticleIdList><ArticleId IdType="pubmed">21310090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jan 24;26(4):562-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18164788</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Apr 16;26(17):2127-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18346824</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 2001 Dec;146(12):2275-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11811679</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 Jul;178(1):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9652423</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2008 Aug;37(1):16-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18454312</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Mar;88(5):2867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">24371061</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20949-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18093945</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2016 Dec;52(6):863-866</Citation><ArticleIdList><ArticleId IdType="pubmed">27379842</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2017 Mar 7;35(10 ):1455-1463</Citation><ArticleIdList><ArticleId IdType="pubmed">28189402</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2013 Feb 06;10:47</Citation><ArticleIdList><ArticleId IdType="pubmed">23384324</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Nov;3(11):e167</Citation><ArticleIdList><ArticleId IdType="pubmed">17997603</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Jun 12;32(28):3473-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24793949</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Jan;88(2):1175-88</Citation><ArticleIdList><ArticleId IdType="pubmed">24227848</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Genet Evol. 2014 Dec;28:130-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25239729</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1993 Jun;194(2):781-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7684877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000030 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000030 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28993601
|texte= Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28993601" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |